on Pentixapharm Holding AG (isin : DE000A40AEG0)
Pentixapharm Reports Third Quarter 2024 Interim Results
Pentixapharm Holding AG has released its interim report for the third quarter of 2024, ending September 30. The company reported a loss of €49k for the period. No revenue was recorded in this stub fiscal year as business operations have not yet started.
The company’s current liabilities stand at €487k, primarily due to the purchase of Pentixapharm AG shares. The spin-off from Eckert & Ziegler SE, scheduled to integrate Pentixapharm AG and Myelo Therapeutics GmbH, was registered after the reporting period.
Pentixapharm anticipates significant fourth-quarter losses, expecting a total loss of around €8 million for the fiscal year. This projection includes results from Pentixapharm AG and Myelo Therapeutics GmbH as of October 2.
The full report is accessible on the company's investor relations website.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Pentixapharm Holding AG news